Liquidia Corporation
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Roger A. Jeffs
- Full Time Employees
- 216
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 419 Davis Drive Morrisville NC United States of America 27560
- IPO Date
- Jul 26, 2018
- CIK
- 0001819576
- Website
- liquidia.com
- Similar Companies
- Business
- Liquidia Corporation Liquidia Corporation (LQDA) is a biopharmaceutical company that develops, manufactures, and commercializes products addressing unmet needs in rare cardiopulmonary diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD); its core offerings center on YUTREPIA, an inhaled dry powder formulation of treprostinil, alongside investigational therapies such as L606, a liposomal sustained-release formulation of treprostinil licensed from Pharmosa Biopharm Inc., and references to related products like Yutopia for inhalation and generic treprostinil options, all leveraging proprietary PRINT particle engineering technology for precise drug particle production. Founded in 2004 and headquartered in Morrisville, North Carolina, the company operates primarily in the United States through wholly owned subsidiaries Liquidia Technologies, Inc. and Liquidia PAH, LLC, targeting patients with rare respiratory conditions via innovative drug delivery systems that enhance convenience and efficacy. Recent developments include a $67.5 million common stock financing in September 2024 comprising a public offering and private placement with Caligan Partners LP, plus a $32.5 million advance under a fifth amendment to its Revenue Interest Financing Agreement with HealthCare Royalty, bringing total non-dilutive funding to $100 million and extending the agreement term to 2031 while supporting YUTREPIA commercialization, pediatric trials, and L606 advancement ahead of expected 2025 launch post-FDA tentative approval for PAH and PH-ILD; third quarter 2025 results highlighted launch momentum for YUTREPIA and improved profitability.
A Look at Liquidia Corp (LQDA) After 8.7% Decline -- GF Value $232.05 vs Price $71.22
Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?
4 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, FLXS, ELMD & AGX
LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
Liquidia Corporation (LQDA) Is Up 9.99% in One Week: What You Should Know
Can Yutrepia Maintain Momentum for LQDA Stock in 2026?
This Liquidia Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
3 Best Low-Beta Stocks to Buy Right Away: LQDA, FLXS & AGX
Liquidia Corporation (LQDA) Shareholder/Analyst Call Prepared Remarks Transcript
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?
Liquidia Announces Poster Presentations at the PHA 2026 International PH Conference and Scientific Sessions
Liquidia Corp (LQDA) Stock Up 3.4% and Still Undervalued -- GF Score: 75/100
Liquidia Corporation Announces Inclusion in the S&P SmallCap 600® Index
4 Best Low-Beta Stocks to Buy Right Away: LQDA, CVX, OXY & VLO
4 Biotech Stocks Investors Should Watch in 2026
State Street SPDR S&P Pharmaceuticals vs First Trust NYSE Arca Biotech: Which Is the Better ETF For Your Portfolio?
Biotech ETFs: Which ETF Offers Lower Fees? IBBQ or XPH?
Are You Looking for a Top Momentum Pick? Why Liquidia Corporation (LQDA) is a Great Choice
Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference
4 Low-Beta Stocks for a Steadier Portfolio: LQDA, XOM, VLO & FANG